Federal regulators have green-lighted Guilford’s AI Therapeutics to begin a clinical trial to test if its experimental drug for non-Hodgkin lymphoma and ALS could also work against COVID-19 … more
Branford’s IsoPlexis has landed a $2 million national grant to expand development of a cellular platform for analyzing the effects of the inflammatory immune response on Alzheimer’s Disease progression … more